Van ECK Associates Corp grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,078,208 shares of the biopharmaceutical company’s stock after purchasing an additional 50,893 shares during the quarter. Van ECK Associates Corp owned approximately 0.08% of Gilead Sciences worth $67,442,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of GILD. Athena Capital Advisors LLC acquired a new stake in Gilead Sciences during the fourth quarter worth about $27,000. Advisors Preferred LLC acquired a new stake in Gilead Sciences during the fourth quarter worth about $31,000. Legacy Financial Advisors Inc. raised its stake in Gilead Sciences by 361.3% during the fourth quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 383 shares during the period. We Are One Seven LLC acquired a new stake in Gilead Sciences during the fourth quarter worth about $37,000. Finally, Larson Financial Group LLC acquired a new stake in Gilead Sciences during the fourth quarter worth about $38,000. Institutional investors and hedge funds own 78.23% of the company’s stock.

NASDAQ GILD opened at $65.63 on Friday. Gilead Sciences, Inc. has a 52 week low of $60.32 and a 52 week high of $80.90. The company has a quick ratio of 3.29, a current ratio of 3.38 and a debt-to-equity ratio of 1.19. The stock has a market capitalization of $82.69 billion, a price-to-earnings ratio of 10.67, a PEG ratio of 4.08 and a beta of 1.16.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 EPS for the quarter, missing the consensus estimate of $1.70 by ($0.26). Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.52 billion. During the same quarter last year, the company posted $1.78 EPS. Gilead Sciences’s revenue for the quarter was down 2.6% on a year-over-year basis. As a group, equities analysts expect that Gilead Sciences, Inc. will post 6.23 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 28th. Shareholders of record on Friday, March 15th will be given a $0.63 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.57. The ex-dividend date is Thursday, March 14th. This represents a $2.52 annualized dividend and a yield of 3.84%. Gilead Sciences’s dividend payout ratio is 37.07%.

Several equities research analysts recently weighed in on the stock. Wells Fargo & Co lowered shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $95.00 to $68.00 in a research note on Monday, February 11th. Guggenheim assumed coverage on shares of Gilead Sciences in a research note on Monday, December 17th. They set a “buy” rating and a $86.00 price objective on the stock. Raymond James set a $90.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Tuesday, February 5th. BidaskClub upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Tuesday, December 4th. Finally, Citigroup cut shares of Gilead Sciences from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $100.00 to $75.00 in a research report on Tuesday, February 12th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $82.29.

In other news, Director Gayle E. Wilson sold 19,068 shares of the stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $67.08, for a total value of $1,279,081.44. Following the completion of the transaction, the director now directly owns 143,567 shares in the company, valued at $9,630,474.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.16% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Stake Raised by Van ECK Associates Corp” was originally published by Marea Informative and is owned by of Marea Informative. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at

Gilead Sciences Profile

Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Further Reading: How do investors use RSI to grade stocks?

Want to see what other hedge funds are holding GILD? Visit to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with's FREE daily email newsletter.